In our lung cancer quiz, you’ll get to test your knowledge on the BFAST study.
What is the significance of the BFAST trial (NCT03178552)?
a. It is a study investigating whether upfront brain radiotherapy is superior to “at progression” brain radiotherapy in patients with non-small cell lung cancer (NSCLC) and asymptomatic brain metastases.
b. It is an ongoing global study evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations in circulating tumor DNA and activity of targeted therapies and immunotherapy in patients with first-line advanced NSCLC.
c. It is a study assessing the effect of molecular testing and the introduction of novel therapeutic options on the use of systemic therapy and overall survival for patients with advanced NSCLC.
d. t is a study assessing the efficacy and safety of AB928 plus carboplatin, pemetrexed, and a PD-1 antibody in patients with metastatic NSCLC.
Quiz: Best Second-Line Tx for Metastatic Lung SCC and Crohn Disease?
March 1st 2018Are there special second-line considerations for an SCC lung patient with a history of Crohn disease who progressed on first-line carboplatin and gemcitabine? Can any pretreatment tests be deferred for a patient with a history of heavy smoking and a single solitary nodule found on his CT chest scan? Take this multiquestion quiz to find out.
Quiz: Are EGFR Mutations and ALK Rearrangements in Lung Cancer Mutually Exclusive?
February 1st 2018Know when to change targeted therapies in patients with progressive lung cancer? How about appropriate patient criteria for segmentectomy or wedge resection? Test your knowledge in our latest quiz.
Quiz: How Common Are ROS1 Rearrangements in Patients With Lung Cancer?
January 1st 2018In patients with stage IIIA non–small-cell lung cancer, should the presence of N2 disease be determined by both radiologic and invasive staging prior to treatment initiation? Are ALK rearrangements and EGFR mutations mutually exclusive? Test your knowledge in our latest quiz.